Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
TARGET-HPV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
- NCT05108870 ↗
- Active, not recruiting
- University of Chicago
- Focused
We haven't built an HCP commentary report on TARGET-HPV (HB-201, HB-202 and 2 more in Human Papilloma Virus) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TARGET-HPV so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Human Papilloma Virus; HPV; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
- Interventions
- HB-201; HB-202; Carboplatin; Paclitaxel; Transoral Robotic Surgery
- Arms
- Phase 1: Dose-Finding Group 1 - Drug Combination 1 · Experimental
- Phase 1: Dose-Finding Group 2 - Drug Combination 2 · Experimental
- Phase 2: Efficacy Arm 1 - HB-201 + Chemotherapy · Experimental
- Phase 2: Efficacy Arm 2 - HB-201 and HB-202 + Chemotherapy · Experimental
- Enrollment
- 35
- Primary outcomes
- Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy
- Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy
- Sponsor
- University of Chicago
- Start
- Aug 22, 2022
- Primary completion
- Jan 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05108870 · updated Apr 24, 2026